Researchers analyzed 36 Phase III clinical trials in the field of gynecologic oncology. They looked at how trial results related to the prestige of the journals where they were published. The study measured several factors, including the number of authors and the length of follow-up time.
The analysis found that trials with positive outcomes were published in journals with significantly higher impact factors than those with negative outcomes. While trials with more authors also showed a link to higher impact factors, only the positivity of the primary outcome was independently associated with a higher journal ranking.
It is important to note that this study shows a statistical association rather than a direct cause. Factors like follow-up duration and sample size did not predict where a study would be published. This finding suggests that negative results might receive less visibility in major journals, which could impact how medical information is shared.
Common questions
What did this study find about trial results and journal rankings?
The analysis of 36 trials showed that studies with positive outcomes were published in journals with significantly higher impact factors than those with negative outcomes. Specifically, the median impact factor for positive outcome trials was 35.1 compared to 24.0 for negative ones.
Did the number of authors or trial size affect where studies were published?
While a higher number of authors was associated with higher impact factors, only the positive outcome of the study was an independent predictor of a higher journal ranking. Factors like sample size and follow-up duration did not significantly predict the journal's impact factor.
What does this mean for medical research visibility?
The findings suggest that trials with positive results may receive more visibility in high-profile journals. This highlights a potential bias where negative results might be less visible, making it important to look at all available data when evaluating new treatments.
